ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
C4 Therapeutics has launched from James E. Bradner’s lab at Dana-Farber Cancer Institute with $73 million in financing. The firm is developing Degronimids, small-molecule binders that target disease-causing proteins and facilitate their clearance from cells through the natural ubiquitin-proteasome system. The molecules offer a promising approach for previously undruggable proteins, it says. At the same time, C4 will work with Roche to develop Degronimids against unspecified targets. The deal could be worth more than $750 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter